iifl-logo

Jubilant Pharmova Ltd Board Meeting

917
(2.36%)
Apr 1, 2025|12:00:00 AM

Jubilant Pharmo CORPORATE ACTIONS

02/04/2024calendar-icon
02/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting31 Jan 202523 Jan 2025
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024. Re Outcome of Board Meeting (As Per BSE Announcement Dated on 31/01/2025)
Board Meeting25 Oct 202417 Oct 2024
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve Intimation of Board Meeting - To consider the unaudited Financial Results for the Quarter and Half Year ended September 30 2024. Outcome of the Board Meeting held on October 25, 2024 - Approval of Unaudited Financial Results for quarter and half year ended September 30, 2024 Approval of Unaudted Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024)
Board Meeting19 Jul 202410 Jul 2024
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/07/2024 inter alia to consider and approve Intimation of Board Meeting -July 19 2024 The Company has submitted to the Stock Exchange the Outcome of Board Meeting held on July 19, 2024 Unaudited Financial Results for June 30, 2024 (As per BSE Announcement Dated on 19/07/2024)
Board Meeting29 May 202422 May 2024
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Intimation of Board Meeting and recommendation of Final Dividend if any. Outcome of Board Meeting (As Per BSE Announcement Dated on: 29/05/2024)

Jubilant Pharmo: Related News

Jubilant Pharmova Passes FDA Audit, Expands R&D with Pierre Fabre
26 Sep 2024|07:42 PM

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.

Read More
FDA Issues VAI Status to Jubilant HollisterStier's Washington Facility
11 Sep 2024|11:23 AM

Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.

Read More
Top 10 stocks for today – 11th September, 2024
11 Sep 2024|09:23 AM

Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.

Read More
Jubilant Pharmova arm to pick up 80% stake in Pierre Fabre’s centre
19 Aug 2024|01:36 PM

Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.